RecruitingNCT05366361

The Dynamics of Human Atrial Fibrillation

Sponsor

Stanford University

Enrollment

200 participants

Start Date

Aug 18, 2020

Study Type

OBSERVATIONAL

Conditions

Atrial Fibrillation Arrhythmias, Cardiac

Summary

Atrial fibrillation (AF) is an enormous public health problem in the United States, affecting 2-5 million Americans and causing rapid heart beats, stroke, heart failure or death. In this project, the applicant will develop a novel framework to better understand human AF that builds on agreement between several concepts for the disease. The applicant will develop strategies to identify AF patients who will best respond to each of several therapies, to guide personalized therapy.

Eligibility

Min Age: 22 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is researching what causes and maintains an irregular heart rhythm called persistent atrial fibrillation (AF) — where the heart beats chaotically and requires a procedure or cardioversion to reset it. Researchers will collect heart data during ablation procedures or surgery to better understand AF patterns. **You may be eligible if...** - You have been referred for an ablation procedure or Maze surgery for persistent atrial fibrillation - Your AF requires a procedure (cardioversion) to stop it or has lasted more than 7 days - You have already tried or cannot tolerate at least one anti-arrhythmic medication **You may NOT be eligible if...** - You have active coronary ischemia (blocked heart arteries causing symptoms) or severe heart failure - You have a blood clot in your heart - You are pregnant - You have rheumatic valve disease - You have a clotting or blood vessel disorder - You are unwilling or unable to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.